Compare ARCT & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | MDWD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.9M | 162.2M |
| IPO Year | 2019 | 2013 |
| Metric | ARCT | MDWD |
|---|---|---|
| Price | $10.74 | $12.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $23.80 | ★ $30.67 |
| AVG Volume (30 Days) | ★ 653.3K | 78.8K |
| Earning Date | 11-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,031,000.00 | N/A |
| Revenue This Year | N/A | $39.60 |
| Revenue Next Year | $64.21 | $34.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $11.84 |
| 52 Week High | $17.96 | $19.70 |
| Indicator | ARCT | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 41.90 |
| Support Level | $6.53 | N/A |
| Resistance Level | $17.85 | $14.06 |
| Average True Range (ATR) | 1.13 | 0.50 |
| MACD | -0.26 | -0.05 |
| Stochastic Oscillator | 8.84 | 21.79 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.